Company: CNTB
Filing Date: 2025-09-10
Form Type: POS AM
Source: 0001193125-25-200186
Chunk: 78

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-09-10
Form: POS AM
Chunk 78
---
 our working capital, and for general corporate purposes.

The amounts and timing of our actual expenditures will depend upon numerous factors, including the progress of our development
and commercialization efforts, the status of and results from our clinical, non-clinical or pre-clinical trials, whether or not we enter into strategic collaborations or
partnerships, and our operating costs and expenditures. Accordingly, our management will have significant flexibility in applying the net proceeds of this offering. In addition, while we have not entered into any outstanding binding agreements or
commitments relating to any significant transaction as of the date of this prospectus, we may use a portion of the net proceeds to pursue acquisitions, joint ventures, and other strategic transactions.

15

CAPITALIZATION The table below sets forth our cash and cash equivalents and capitalization as of June 30, 2025, the latest date for which we have unaudited interim financial statements and the information below available to us:

| • |     | on an actual basis; |

| • |     | on a pro forma basis to reflect the issuance and sale of $150,000,000 of Ordinary Shares in this offering at                                                                                                                                          
 an assumed offering price of $1.76 per Ordinary Share, the last reported sale price of our Ordinary Shares on the Nasdaq Global Market on September 9, 2025, after deducting the estimated commissions and estimated offering expenses payable by us. |

The pro forma information below is illustrative only, and our capitalization following the completion of this offering will be adjusted based on the actual offering price, the actual number of Ordinary Shares offered by us and other terms of this offering determined at pricing. You should read this table in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus and “Use of Proceeds,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-Kfor the year ended December 31, 2024, as updated by our Quarterly Reports on Form 10-Qfor the quarters ended March 31, 2025 and June 30, 2025. The following information should be read in conjunction with the unaudited, condensed consolidated financial statements and related notes incorporated by reference in this prospectus. For more details on how you can obtain the documents incorporated by reference in this prospectus, see “Where You Can Find More Information; Incorporation by Reference”.

|                                      |     | As of June 30, 2025 |          |